Dr. Reddy's Labs ADR files Form 20-F, shares stay tied to US pharma peers
26.06.2026 - 22:47:57 | ad-hoc-news.de
By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-26, 22:47.
Dr. Reddy's Laboratories (US2565981035) has filed its latest annual report on Form 20-F with the US Securities and Exchange Commission. The Indian generics specialist is listed on Nasdaq via American Depositary Receipts (ADR), giving US investors direct exposure to its pharma business as disclosed in the new filing.
What the new Form 20-F filing covers
According to a company announcement distributed via newswire services, Dr. Reddy's Laboratories Limited submitted its Form 20-F annual report for the latest fiscal year to the SEC, fulfilling its reporting duties as a foreign private issuer to US regulators.The SEC-hosted Form 20-F document provides the detailed financial and risk disclosures that US investors rely on for foreign listings.
The Form 20-F contains audited financial statements under IFRS, a discussion of operating performance in the United States, India and other markets, descriptions of manufacturing facilities, and an extensive section on risks such as price pressure in generics and regulatory compliance in major markets.The company investor relations page bundles the report with recent earnings materials, enabling investors to compare headline figures with the detailed annual disclosure.
Position among global pharma and generic peers
With its ADRs trading in New York, Dr. Reddy's sits in a peer group including Teva Pharmaceutical, Viatris and Sun Pharma for investors tracking global generic and specialty pharma names on US venues such as Nasdaq and NYSE.Reuters data on RDY and its sector peers shows that these companies compete in areas like complex generics, injectables and active pharmaceutical ingredients, often facing similar pricing and regulatory dynamics.
Analyst coverage of Dr. Reddy's on international data platforms indicates a mixed but constructive view, with several brokers highlighting the US business contribution and the importance of maintaining a robust product pipeline for specialty medicines.Consensus estimates compiled by MarketScreener for the local Indian listing are frequently referenced by institutional investors when evaluating the ADR valuation in New York.
All news and analysis on the Dr. Reddy's Labs (ADR) shares
Track further corporate filings, earnings and analyst commentary on Dr. Reddy's Labs (ADR) with our continuously updated topic overview.
How Dr. Reddy's makes its money
Dr. Reddy's generates revenue primarily from generic and branded formulations, active pharmaceutical ingredients and biosimilars, with a strong presence in the United States, India, Russia and other emerging markets, while investing in specialty products to support margin resilience.
Where the stock trades today
Dr. Reddy's Labs (ADR) most recently traded on Nasdaq under the ticker RDY at around 75.00 US dollars per ADR, based on late US trading data as of 2026-06-26.
Dr. Reddy's Labs (ADR) at a glance
- Company: Dr. Reddy's Laboratories Ltd.
- ISIN: US2565981035
- WKN: 895250
- Ticker: RDY
- Trading venue: NASDAQ
- Price (as of 2026-06-26, 20:30): 75.00 USD
- Market cap: 12.0 billion USD (as of 2026-06-26)
- Sector / industry: Health Care / Pharmaceuticals
- Index membership: Nifty 50 (for the primary Indian listing)
- Next earnings date: not officially scheduled
This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.
